AN2 Therapeutics, Inc. (ANTX)
Market Cap | 63.54M |
Revenue (ttm) | n/a |
Net Income (ttm) | -66.03M |
Shares Out | 29.83M |
EPS (ttm) | -2.54 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 36,399 |
Open | 2.100 |
Previous Close | 2.130 |
Day's Range | 2.075 - 2.140 |
52-Week Range | 1.910 - 22.220 |
Beta | -0.15 |
Analysts | Hold |
Price Target | 5.00 (+134.74%) |
Earnings Date | Aug 8, 2024 |
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ANTX stock is "Hold." The 12-month stock price forecast is $5.0, which is an increase of 134.74% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/8/e/press9-2430628.jpg)
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/p/g/press7-2347216.jpg)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/d/l/press7-2319107.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised to...
![](https://cdn.snapi.dev/images/v1/f/t/press8-2309710.jpg)
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX)
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible ...
![](https://cdn.snapi.dev/images/v1/j/d/press1-2309113.jpg)
ANTX ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AN2 Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible ...
![](https://cdn.snapi.dev/images/v1/f/a/press10-2299682.jpg)
AN2 Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANTX
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi...
![](https://cdn.snapi.dev/images/v1/j/r/press12-2296641.jpg)
AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi...
![](https://cdn.snapi.dev/images/v1/d/i/press9-2272949.jpg)
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AN2 Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AN2 Therapeut...
![](https://cdn.snapi.dev/images/v1/j/6/biotech29-2271072.jpg)
AN2 Therapeutics to pause lung disease study enrollment
AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-e...
![](https://cdn.snapi.dev/images/v1/3/b/press20-2271048.jpg)
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/i/1/conf20-2251758.jpg)
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/h/g/press20-2151151.jpg)
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/z/5/conf9-2141156.jpg)
AN2 Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/y/z/press20-2108329.jpg)
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/l/d/conf8-2098072.jpg)
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/a/b/press8-2077544.jpg)
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/g/r/press11-2061110.jpg)
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/p/z/press5-2024713.jpg)
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/e/j/press20-2018460.jpg)
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/e/k/conf8-1908457.jpg)
AN2 Therapeutics to Present at Jefferies Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/w/k/press16-1886336.jpg)
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/2/o/conf1-1862701.jpg)
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/a/w/press20-1817828.jpg)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/g/p/conf18-1775447.jpg)
AN2 Therapeutics to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
![](https://cdn.snapi.dev/images/v1/9/k/conf19-1731919.jpg)
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious dise...